TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07187973: A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Sponsor: Disc Medicine, Inc · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$993,344

Rescue Site Savings

+$654,704

Unlock Full NCT07187973 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07187973 Rescue Dossier →